PRIDE III Prison Interventions and HIV Prevention Collaboration

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Yale University
Study ID
NCT06962033
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Opioid Agonist Therapy — BEHAVIORAL
    Opioid Agonist Therapy (OAT) as HIV prevention

Study Details

The primary objective of this research project is to identify barriers to scale-up of Opioid Agonist Therapy (OAT) in the justice systems (prisons and probation) in Tajikistan, Kyrgyzstan, Moldova, and Georgia, and establish a NIATx learning collaborative to scale-up OAT, and analyze scale-up utilizing latent class growth analyses in people who inject drugs (PWID).

Key Dates

Start date
Nov 5, 2024
Status verified
May 2025
Primary completion
Dec 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
300 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: Aim 1- Implementation
    Scale-up Opioid Agonist Therapy (OAT) as HIV prevention in prisons and pre-trial detention centers in EECA for individuals with Opioid Use Disorder (OUD) and link them to community treatment after release using development of NIATx learning collaboratives with prison OAT providers (addiction care specialists or primary care doctors). OAT scale-up data will be collected from each country's national OAT database, as well as administration of survey to prison narcologists.
  • Experimental: Aim 2- Scale-Up
    Scale-up OAT as HIV prevention in the newly formed probation system in EECA for individuals with OUD and link them to OAT treatment as part of routine care to align public safety and public health using development of NIATx learning collaboratives with probation and prison officers in Kyrgyzstan, Tajikistan, Moldova, and Georgia. OAT scale-up data will be collected from each member country's national OAT database, and administer a survey to probation officers.

Primary Outcome Measure

Number of participants receiving opioid agonist therapy (OAT) [ Time Frame: baseline up to 4 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Yale UniversityNew HavenConnecticut06520-

Find similar trials in New Haven, CT

By condition
HIVSubstance use disorder
By specialty
Infectious diseaseBehavioral healthAddiction medicine
By research site
Yale University· New Haven, CT

Related Studies